3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
5
Other hematologic neoplasm
3
Breast
3
Gastrointestinal
2
Myeloid
1
Gynecologic
1
Conditions
Neoplasms
2
Colorectal Neoplasms
2
Prostatic Neoplasms
1
Motor Activity
1
Eye Diseases
1
Cognitive Dysfunction
1
Cardiovascular Diseases
1
Interventions
Oxaliplatin
1004
Fluorouracil
800
Capecitabine
764
Gemcitabine
650
Leucovorin
559
Irinotecan
537
Bevacizumab
513
Radiotherapy
460
Cisplatin
440
Drug Therapy
298
Cetuximab
280
Surgical Procedures, Operative
229
Paclitaxel
228
S 1 (combination)
217
pembrolizumab
205
Docetaxel
199
130-nm albumin-bound paclitaxel
196
Nivolumab
193
sintilimab
191
Radiosurgery
190
lenvatinib
180
Folfox protocol
179
Sorafenib
178
Albumin-Bound Paclitaxel
173
apatinib
170
tislelizumab
161
camrelizumab
160
Neoadjuvant Therapy
158
Blood Specimen Collection
154
durvalumab
148
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Geritol
×
Gastrointestinal
×
Clear all
NCT07341217
2026-01-14
CHEMOBRAIN
Lancaster University
Phase NA
Not yet recruiting
86 enrolled
NCT00270647
2018-02-28
PHS II
Brigham and Women's Hospital
Phase NA
Completed
14,641 enrolled